Cencora (COR) has witnessed a flurry of investment activity. JPMorgan Chase predicts a rise in stock price, with many analysts sharing their own supportive views. This sentiment is due to Cencora's strong momentum as a value and growth stock. Despite the retirement of two board members, the company remains a strong force in the market. Cencora's shares have been sold by Walgreens Boots Alliance for an approximate of $1.1 billion, subsequently acquired by multiple investment firms, suggesting a high level of interest. Cencora's earnings call set for Q1 2025 is an awaited event, following the company's strong performance in Q4 2024. The corporation recently completed a $4.4 billion acquisition of Retina Consultants, promising a positive impact on its 2025 EPS outlook. Despite this, Cencora's shares have slipped 2.8% since its last earnings report. However, Cencora plans to fund its strategic healthcare acquisition through a $1.8 billion Senior Notes Offering. Additionally, the company has facilitated key internal appointments, expanded their enterprise leadership team, and boosted its dividend, suggesting a focus on both internal growth and shareholder returns.
Cencora COR News Analytics from Wed, 22 May 2024 07:00:00 GMT to Sat, 25 Jan 2025 16:58:49 GMT -
Rating 8
- Innovation -2
- Information 5
- Rumor -3
